High ROIC Stocks
GILD is currently part of our High ROIC Stocks screen, indicating it generates strong returns on invested capital.
GILEAD SCIENCES INC (GILD) Stock Price & Overview
NASDAQ:GILD • US3755581036
Current stock price
139.71 USD
-0.59 (-0.42%)
At close:
139.89 USD
+0.18 (+0.13%)
After Hours:
The current stock price of GILD is 139.71 USD. Today GILD is down by -0.42%. In the past month the price decreased by -3.74%. In the past year, price increased by 30.27%.
GILD Key Statistics
52-Week Range93.37 - 157.29
Current GILD stock price positioned within its 52-week range.
1-Month Range133.89 - 149.38
Current GILD stock price positioned within its 1-month range.
- Market Cap
- 173.439B
- P/E
- 17.14
- Fwd P/E
- 15.81
- EPS (TTM)
- 8.15
- Dividend Yield
- 2.40%
GILD Stock Performance
Today
-0.42%
1 Week
+2.07%
1 Month
-3.74%
3 Months
+14.89%
Longer-term
6 Months +23.98%
1 Year +30.27%
2 Years +114.28%
3 Years +69.94%
5 Years +120.12%
10 Years +58.38%
GILD Stock Chart
GILD Stock Screens
GILD currently appears in the following ChartMill screener lists.
High Free Cash Flow Stocks
GILD is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
Best Dividend Stocks
GILD is currently part of our Best Dividend Stocks screen, indicating it pays a high and sustainable dividend.
Safe Dividend Stocks
GILD occurs in our Safe Dividends Stock Screen, indicating it has a high and sustainable dividend, while being financially healthy
GILD Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to GILD. When comparing the yearly performance of all stocks, GILD is one of the better performing stocks in the market, outperforming 77.58% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
GILD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GILD. GILD scores excellent on profitability, but there are some minor concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GILD Earnings
On February 10, 2026 GILD reported an EPS of 1.86 and a revenue of 7.92B. The company beat EPS expectations (0.73% surprise) and beat revenue expectations (0.98% surprise).
Next Earnings DateApr 23, 2026
Last Earnings DateFeb 10, 2026
PeriodQ4 / 2025
EPS Reported$1.86
Revenue Reported7.925B
EPS Surprise 0.73%
Revenue Surprise 0.98%
GILD Forecast & Estimates
38 analysts have analysed GILD and the average price target is 161.06 USD. This implies a price increase of 15.28% is expected in the next year compared to the current price of 139.71.
For the next year, analysts expect an EPS growth of 8.46% and a revenue growth 3.47% for GILD
Analysts
Analysts81.05
Price Target161.06 (15.28%)
EPS Next Y8.46%
Revenue Next Year3.47%
GILD Groups
Sector & Classification
Sector
Health Care Sub-Industry
Biotechnology GILD Financial Highlights
Over the last trailing twelve months GILD reported a non-GAAP Earnings per Share(EPS) of 8.15. The EPS increased by 76.79% compared to the year before.
Income Statements
Revenue(TTM)29.44B
Net Income(TTM)8.51B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.9% | ||
| ROA | 14.42% | ||
| ROE | 37.49% | ||
| Debt/Equity | 0.97 |
Chartmill High Growth Momentum
EPS Q2Q%-2.11%
Sales Q2Q%4.7%
EPS 1Y (TTM)76.79%
Revenue 1Y (TTM)2.4%
GILD Ownership
Ownership
Inst Owners92.51%
Shares1.24B
Float1.24B
Ins Owners0.08%
Short Float %1.61%
Short Ratio2.65
GILD Latest News, Press Relases and Analysis
GILD Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GILD
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.
Company Info
IPO: 1992-01-22
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA 94404 US
CEO: Daniel P. O'Day
Employees: 17000
Phone: 13026587581
GILEAD SCIENCES INC / GILD FAQ
What does GILEAD SCIENCES INC do?
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.
What is the current price of GILD stock?
The current stock price of GILD is 139.71 USD. The price decreased by -0.42% in the last trading session.
Does GILD stock pay dividends?
GILEAD SCIENCES INC (GILD) has a dividend yield of 2.4%. The yearly dividend amount is currently 3.22.
What is the ChartMill technical and fundamental rating of GILD stock?
GILD has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is GILEAD SCIENCES INC worth?
GILEAD SCIENCES INC (GILD) has a market capitalization of 173.44B USD. This makes GILD a Large Cap stock.
Can you provide the ownership details for GILD stock?
You can find the ownership structure of GILEAD SCIENCES INC (GILD) on the Ownership tab.
What is the Short Interest ratio of GILEAD SCIENCES INC (GILD) stock?
The outstanding short interest for GILEAD SCIENCES INC (GILD) is 1.61% of its float.